Douglas Miehm
Stock Analyst at RBC Capital
(3.74)
# 755
Out of 5,124 analysts
59
Total ratings
58.7%
Success rate
8.26%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $234 → $235 | $188.97 | +24.36% | 8 | Dec 10, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $17 → $19 | $17.08 | +11.24% | 14 | Nov 14, 2025 | |
| MNKD MannKind | Maintains: Outperform | $8 → $7.5 | $5.67 | +32.28% | 4 | Nov 11, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Sector Perform | $9 → $15 | $15.95 | -5.96% | 11 | Nov 5, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $6.95 | +43.88% | 21 | May 2, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $0.87 | +472.08% | 1 | Mar 10, 2025 |
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $234 → $235
Current: $188.97
Upside: +24.36%
Bausch + Lomb
Nov 14, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $17.08
Upside: +11.24%
MannKind
Nov 11, 2025
Maintains: Outperform
Price Target: $8 → $7.5
Current: $5.67
Upside: +32.28%
Aurinia Pharmaceuticals
Nov 5, 2025
Downgrades: Sector Perform
Price Target: $9 → $15
Current: $15.95
Upside: -5.96%
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $6.95
Upside: +43.88%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $0.87
Upside: +472.08%